BioVex was founded in 1999, based on research by Robert Coffin at University College London, and moved its headquarters to Woburn, Massachusetts in 2005, leaving about half its employees in the UK.The phase II clinical trial in melanoma was published in 2009 and the phase III trial was published in 2013.Talimogene laherparepvec was approved by the U.S. Food and Drug Administration to treat melanoma in October 2015. It was the first approval of an oncolytic virus and the first approval of a gene therapy in the West. It was approved by the European Medicines Agency in December of that year. Society and culture
Economics
Amgen estimated that talimogene laherparepvec would be priced at US$65,000 per patient at the time it was approved. International Press
The Conversation (website)  which has multilingual articles, published in French and Spanish in October 2022 the following article by  Arthur Battistoni  and Françoise Debierre-Grockiego both of the University of Tours 

Immunotherapy a parasite of dogs that helps fight incurable skin cancers

Research
As of 2016, talimogene laherparepvec has been studied in early stage clinical trials in pancreatic cancer, soft-tissue sarcoma, and head and neck squamous-cell carcinoma; it had also been tested in combination with checkpoint inhibitors ipilimumab and pembrolizumab. See also
Virotherapy
Oncolytic adenovirus

Notes
References
External links
"Talimogene laherparepvec". Drug Information Portal. U.S. National Library of Medicine.
Some physicians favor administering the maximum safe dose (calculated based on a number of factors), while others favor administering smaller doses, which may still be effective in ablating all thyroid tissue. I-131 is used for ablation of the thyroid tissue. Minimally invasive thyroidectomy has been used in recent years in cases where the nodules are small. Finding disease recurrence
Some studies have shown that thyroglobulin (Tg) testing combined with neck ultrasound is more productive in finding disease recurrence than full- or whole-body scans (WBS) using radioactive iodine. However, current protocol (in the USA) suggests a small number of clean annual WBS are required before relying on Tg testing plus neck ultrasound. When needed, whole body scans consist of withdrawal from thyroxine medication and/or injection of recombinant human Thyroid stimulating hormone (TSH). In both cases, a low iodine diet regimen must also be followed to optimize the takeup of the radioactive iodine dose. Low dose radioiodine of a few millicuries is administered. Full body nuclear medicine scan follows using a gamma camera. Scan doses of radioactive iodine may be I131 or I123. Recombinant human TSH, commercial name Thyrogen, is produced in cell culture from genetically engineered hamster cells.